Role of TIM-3 in ovarian cancer: the forsaken cop or a new noble

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Aug. 13, 2024

T cell immunoglobulin and mucin domain-3 (TIM-3), a crucial immune checkpoint following PD1 CTLA4, is widely found in several cells. Nonetheless, its performance recent clinical trials appears disappointing. Ovarian cancer (OC), malignant tumor with high mortality rate gynecology, faces significant hurdles immunotherapy. The broad presence of TIM-3 offers new opportunity for immunotherapy OC. This study reviews the role OC assesses potential as target regulatory effects on microenvironment are discussed, focus preclinical studies that demonstrate TIM-3’s modulation various cells Additionally, therapeutic advantages challenges targeting examined.

Language: Английский

---

The capability of heterogeneous γδ T cells in cancer treatment

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Nov. 24, 2023

γδ T cells, a specialized subset of lymphocytes, have garnered significant attention within the realm cancer immunotherapy. Operating at nexus between adaptive and innate immunological paradigms, these cells showcase profound tumor discernment repertoire, hinting novel immunotherapeutic strategies. Significantly, possess capability to directly identify eliminate without reliance on HLA-antigen presentation. Furthermore, faculty present antigens αβ amplifying their anti-tumoral efficacy.Within diverse heterogeneous subpopulations distinct immune functionalities emerge, manifesting either anti-tumor or pro-tumor roles microenvironment. Grasping strategically harnessing cell cohorts is pivotal integration in tumor-specific modalities. The aim this review describe heterogeneity lineage functional plasticity it generates treatment malignant tumors. This endeavors elucidate intricate inherent lineage, consequential dynamics combating malignancies, latest advancements from clinical trials, evolving landscape cell-based oncological interventions, while addressing challenges impeding field.

Language: Английский

---

γδ T Lymphocytes as a Double-Edged Sword—State of the Art in Gynecological Diseases

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(23), P. 14797 - 14797

Published: Nov. 26, 2022

Human gamma-delta (γδ) T cells are a heterogeneous cell population that bridges the gap between innate and acquired immunity. They involved in variety of immunological processes, including tumor escape mechanisms. However, by being prolific cytokine producers, these lymphocytes also participate antitumor cytotoxicity. Which one two possibilities takes place depends on microenvironment (TME) subpopulation γδ lymphocytes. The aim this paper is to summarize existing knowledge about phenotype dual role cancers, ovarian cancer (OC). OC third most common gynecological lethal malignancy. Anticancer immunity modulated TME, immunosuppressive cells, cytokines, soluble factors. Immune exposed TME many signals determine their immunophenotype can manipulate functions. significance pathophysiology enigmatic remains be investigated.

Language: Английский

---

γδ T cell immunotherapy: Requirement for combinations?

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 61 - 76

Published: Oct. 25, 2024

Language: Английский

---

Appraising γδ T cell exhaustion and differentiation in the context of synthetic engineering for cancer immunotherapy

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 77 - 102

Published: Oct. 25, 2024

Language: Английский

---